Introduction to Mpox Surveillance Challenges

The global re-emergence of Mpox has placed national health systems under intense pressure. Effective Mpox surveillance preparedness is essential to detect cases early and prevent large-scale outbreaks. Recently, a cross-sectional study in Ethiopia evaluated how ready the disease surveillance system is to handle such threats. The results suggest that while some awareness exists, significant systemic barriers remain. Health professionals at various levels shared their insights, revealing a divided perception of the country's actual readiness.

Key Findings from the Surveillance Evaluation

The study surveyed 42 disease surveillance professionals across federal and regional levels. Surprisingly, only 45.3% of these experts believed the current system could effectively respond to an outbreak. Conversely, 54.7% expressed doubt, highlighting a lack of confidence in the existing infrastructure. Researchers identified several major obstacles, such as inadequate diagnostic capacity and fragmented coordination. For instance, 83.3% of respondents felt that laboratory facilities were insufficient for rapid detection. Furthermore, 78.6% of those surveyed noted the absence of specific contingency plans for Mpox.

Critical Gaps in Infrastructure and Resources

Resource allocation remains a primary concern for strengthening Mpox surveillance preparedness. The survey indicated that 59.5% of organizations did not have stockpiles of personal protective equipment (PPE). Additionally, 57.1% of professionals reported that their staff lacked specialized training on Mpox protocols. These findings suggest that without targeted interventions, surveillance systems might fail to catch initial cases. Therefore, policymakers must prioritize training and resource distribution to ensure frontline workers are equipped. Strengthening these areas will improve the overall ability to manage emerging health threats effectively.

Mpox surveillance preparedness: Global and Local Implications

The challenges identified in Ethiopia reflect broader trends seen in many developing health systems. Fragmented communication across different sectors often leads to delayed responses. Moreover, the lack of standardized protocols creates confusion during a crisis. To address these issues, health authorities should implement integrated surveillance models. These models focus on cross-sector coordination and equitable resource allocation. By learning from these professional perspectives, countries can refine their public health strategies to better protect their populations.

Frequently Asked Questions

What are the main gaps in Mpox surveillance?

The primary gaps include limited laboratory diagnostic capacity, lack of specialized staff training, and insufficient stockpiles of personal protective equipment.

How can coordination be improved during an outbreak?

Strengthening cross-sector communication and establishing clear contingency plans are vital steps for better coordination and faster response times.

Why is laboratory capacity so critical for Mpox?

Rapid laboratory testing is the only way to confirm cases and distinguish Mpox from other febrile rash illnesses, which is essential for effective isolation and contact tracing.

Disclaimer: This content is for informational and educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Zewdie GA et al. A rapid evaluation of the preparedness of Ethiopia's disease surveillance system for Mpox outbreak: a cross-sectional study of perspectives from professionals across various levels. Trop Med Health. 2026 Jun 06. doi: 10.1186/s41182-026-00994-8. PMID: 42251460.
2. World Health Organization. Multi-country outbreak of mpox, External situation report #66 - 31 May 2026. Available at: https://www.who.int/emergencies/situations/monkeypox-oubreak-2022.
3. Ministry of Health and Family Welfare, Government of India. Guidelines for Management of Mpox Disease. 2024-2025.